Charting the research frontier for viral infections, immunomodulation, and dementia: a perspective on synaptic biomarkers as essential clinical trial endpoints

The viral-inflammatory hypothesis of Alzheimer’s disease offers a new paradigm, yet interventions like antivirals and vaccination present a paradox that challenge therapeutic development. This perspective examines the critical research gap concerning cerebrospinal fluid (CSF) synaptic biomarkers in immunomodulatory therapy trials. Following decades of partially successful amyloid-centric trials, focus has shifted to upstream triggers including viral infections like Herpes Simplex Virus Type 1, Varicella Zoster Virus, and Severe Acute Respiratory Syndrome Coronavirus 2. While large observational and quasi-experimental studies suggest antivirals and vaccines reduce long-term dementia risk, the first major antiviral randomized controlled trial (Valacyclovir for Alzheimer’s Disease) was negative. This perspective posits that this paradox arises from a fundamental flaw in trial design: the absence of synaptic integrity biomarkers. Synaptic loss, not amyloid or tau burden, is the strongest correlate of cognitive decline. Therefore, CSF synaptic protein biomarkers such as the prognostic YWHAG: NPTX2 ratio, postsynaptic Neurogranin (Ng), and presynaptic Growth-Associated Protein 43 (GAP-43) are the most clinically relevant endpoints. The paradoxical trial results may arise from omitting these synaptic measures, creating a mechanistic “black box” obscuring their true biological effects. A strategic framework is proposed, centered on the mandatory inclusion of CSF synaptic biomarkers and relevant co-pathology markers like TAR DNA-Binding Protein 43 (TDP-43; a proteinopathy linked to viral triggers) in all antiviral and vaccine trials. This approach is critical to resolve existing paradoxes, elucidate mechanisms of neuroprotection, and accelerate developing effective therapies that preserve synaptic integrity to prevent and treat dementia.

• Publication year

  2026

• Venue

  Frontiers in Cellular and Infection Microbiology

• Publication date

  2026-01-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fcimb.2025.1701760PMID 41561087PMCID 12813093
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A natural experiment on the effect of herpes zoster vaccination on dementia

  2025cited by this paper
• Age-dependent phenotypes of cognitive impairment as sequelae of SARS-CoV-2 infection

  2025cited by this paper
• The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho‐tau Round Robin study

  2025cited by this paper
• A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer’s disease

  2025cited by this paper
• The Role of TDP-43 in SARS-CoV-2-Related Neurodegenerative Changes

  2025cited by this paper
• Chronic traumatic encephalopathy in athletes, players, boxers and military: systematic review

  2024cited by this paper
• The “Hit and Run” Hypothesis for Alzheimer’s Disease Pathogenesis

  2024cited by this paper
• Neuropathologic and Clinical Findings in Young Contact Sport Athletes Exposed to Repetitive Head Impacts

  2023cited by this paper
• Tackling Dementia Together via The Australian Dementia Network (ADNeT): A Summary of Initiatives, Progress and Plans

  2023cited by this paper
• Tau activation of microglial cGAS–IFN reduces MEF2C-mediated cognitive resilience

  2023cited by this paper
• Potential Involvement of Varicella Zoster Virus in Alzheimer’s Disease via Reactivation of Quiescent Herpes Simplex Virus Type 1

  2022cited by this paper
• CSF GAP-43 as a biomarker of synaptic dysfunction is associated with tau pathology in Alzheimer’s disease

  2022cited by this paper
• Herpesvirus infections, antiviral treatment, and the risk of dementia—a registry‐based cohort study in Sweden

  2021cited by this paper
• The viral hypothesis: how herpesviruses may contribute to Alzheimer’s disease

  2021cited by this paper
• Antiviral therapy: Valacyclovir Treatment of Alzheimer’s Disease (VALAD) Trial: protocol for a randomised, double-blind, placebo-controlled, treatment trial

  2020cited by this paper
• The integrated stress response: From mechanism to disease

  2020cited by this paper
• Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors

  2019cited by this paper
• Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report

  2019cited by this paper
• Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections—a Nationwide, Population-Based Cohort Study in Taiwan

  2018cited by this paper
• NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease

  2018cited by this paper
• Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology

  2018cited by this paper
• Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers

  2017cited by this paper
• Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease

  2016cited by this paper
• Trained immunity: A program of innate immune memory in health and disease

  2016cited by this paper
• Microbes and Alzheimer's Disease.

  2016cited by this paper
• Amyloid-b peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease

  2016cited by this paper
• Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.

  2015cited by this paper
• TDP-43 is a key player in the clinical features associated with Alzheimer’s disease

  2014cited by this paper
• Innate immune activation in neurodegenerative disease

  2014cited by this paper
• Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

  2014cited by this paper
• Faculty Opinions recommendation of The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide.

  2010cited by this paper
• The Alzheimer's Disease-Associated Amyloid β-Protein Is an Antimicrobial Peptide

  2010cited by this paper
• PSEN1 polymorphisms alter the rate of cognitive decline in sporadic Alzheimer's disease patients.

  2009cited by this paper
• Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment.

  2006cited by this paper
• Involvement of Apolipoprotein E in the Hematogenous Route of Herpes Simplex Virus Type 1 to the Central Nervous System

  2002cited by this paper
• Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

  1991cited by this paper
• Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity

  1990cited by this paper
• Viruses, brain and immunosuppression

  1986cited by this paper

• No citing papers are available for this paper.